Fate can be altered
Discovering and developing first-in-class small molecule drugs for improved treatment of diseases with significant clinical need.
More info More infoVision
We aim to become globally recognized for developing breakthrough therapies to treat incurable diseases. Through intelligent identification and validation of protein and mRNA targets that drive disease progression and modulating their activity with small molecules, we strive to change the fate of patients by stopping the progression and reversing the effects of diseases with unmet medical need.
More info More infoPipeline
Molecure’s exceptional in-house medicinal chemistry, biology and discovery capabilities allied to novel target biology gained from leading universities worldwide has enabled us to create a broad pipeline of drug candidates targeting unique and unexplored protein targets, as well as a cutting-edge small molecule mRNA targeting discovery platform.
Discover our pipeline Discover our pipelineNews
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure at the threshold of a breakthrough in the treatment of inflammatory and fibrotic diseases. The focus on the most breakthrough therapy and the OATD-01 and OATD-02 clinical trials results in a reduction of programs in the discovery phase from five to three
Molecure (WSE: MOC) and Nasdaq-listed biotechnology company Ocean Biomedical (NASDAQ: OCEA) sign an exclusive licensing agreement for the development and commercialization of selective YKL-40 inhibitors
Invitation to investor meeting 16th October 2024, 10:00 am (CET)
Join us
People are the foundation of Molecure’s success. Our scientists are the creators of the best ideas for the multiple new small molecule medicines that are invented in the laboratories. The Molecure team works together to discover the therapies needed to improve the treatment of previously incurable diseases.
It is this unified goal that guides us every day. We are inspired by science, we discover and create. For us, work is a passion.